Detalhe da pesquisa
1.
International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.
Pharmacol Rev
; 66(1): 1-79, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24218476
2.
Glucose-dependent insulinotropic polypeptide receptor antagonist treatment causes a reduction in weight gain in ovariectomised high fat diet-fed mice.
Br J Pharmacol
; 179(18): 4486-4499, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35710141
3.
Loss of Function Glucose-Dependent Insulinotropic Polypeptide Receptor Variants Are Associated With Alterations in BMI, Bone Strength and Cardiovascular Outcomes.
Front Cell Dev Biol
; 9: 749607, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34760890
4.
Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors.
Biochem Pharmacol
; 150: 97-107, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29378179
5.
The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor.
Diabetes
; 66(9): 2363-2371, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28667118
6.
Structural Diversity in Conserved Regions Like the DRY-Motif among Viral 7TM Receptors-A Consequence of Evolutionary Pressure?
Adv Virol
; 2012: 231813, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22899926